Press Releases from Cognision (1 total)
Cognision Partners with Anavex for Phase 2 Study of ANAVEX®3-71 Compound
FOR IMMEDIATE RELEASE
Anavex (AVXL) Partners with Cognision for Study of ANAVEX®3-71 in Subjects with Schizophrenia
4/22/2024 - Cognision, providers of advanced neurobiomarker technology, announces its partnership with Anavex Life Sciences Corp. (Nasdaq: AVXL), in a phase 2 clinical trial of ANAVEX®3-71 in subjects with schizophrenia.
ANAVEX®3-71 is a therapeutic agent with a dual mechanism of action, a SIGMAR1 receptor agonist and M1 positive allosteric modulator. This novel mechanism offers the potential…
